ArticleWorld journal of hepatology2025
Ultrasound imaging-guided protocol for monitoring tumor growth in orthotopic rat model of hepatocellular carcinoma.
Article in World journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- PEGylated liposomes enhance the pharmacokinetics, biodistribution, anticancer efficacy, and safety of Kaempferol, a phytomolecule enrolled in clinical trials.Scientific reports · 2026Article
- Ultrasound imaging in orthotopic hepatocellular carcinoma models: Promise, practicality, and points for refinement.World journal of hepatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSyngeneic orthotopic tumor models offer an optimal functional tumor-immune interface for hepatocellular carcinoma research. Yet, unpredictable growth kinetics and spontaneous regression pose major obstacles. Efficient induction protocols and continuous monitoring are therefore essential. Routine exploratory surgeries are ethically untenable, making non-invasive imaging modalities attractive alternatives. High-resolution magnetic resonance imaging and microcomputed tomography deliver detailed insights but incur substantial equipment costs, radiation risks, time demands, and require specialized expertise-challenges that limit their routine use. In contrast, ultrasound (US) imaging emerges as a cost-effective, radiation-free, and rapid approach, facilitating practical and ethical longitudinal assessment of tumor progression in preclinical studies.
aimTo optimize the orthotopic hepatocellular carcinoma model and evaluate the potential of US imaging for accurate and cost-effective tumor monitoring.
methodsHepatocellular carcinoma was induced in 28 Sprague Dawley rats by implanting 5 × 10
resultsUS images procured 7-day post-surgery revealed a well-defined hypoechoic nodule at the left liver lobe tip, confirming successful tumor induction (mean volume 130 ± 39 mm³). Only three animals exhibited spontaneous regression by week 2, underscoring the model's stability. Sorafenib treatment elicited a marked tumor reduction (678 ± 103 mm³)
conclusionThe results demonstrate that US imaging is a reliable, cost-effective, and animal sparing approach with an easy to-master protocol, enabling monitoring of tumor progression and therapeutic response in orthotopic liver tumor models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.